Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | 2141 V-11 + D2C7-IT |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
2141 V-11 | 2141 V11|2141-V11 | CD40 Antibody 14 | 2141 V-11 is a human anti-CD40 antibody with modified Fc domain, which potentially enhances antitumor immune response and inhibits tumor growth (PMID: 30297432). | |
D2C7-IT | D2C7-(scdsFv)-PE38KDEL | D2C7-IT is an immunotoxin engineered by linking a fragment of the D2C7 monoclonal antibody recognizing wild-type EGFR and EGFRvIII with Pseudomonas Exotoxin A (PE38KDEL), which targets tumor cells expressing wild-type EGFR and/or EGFRvIII, potentially resulting in decreased tumor growth (PMID: 28286803, PMID: 31142380). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06455605 | Phase Ib/II | 2141 V-11 + D2C7-IT | D2C7-IT + 2141-V11 Combination Post-resection in rGBM | Not yet recruiting | USA | 0 |
NCT05734560 | Phase Ib/II | 2141 V-11 + D2C7-IT | D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients | Recruiting | USA | 0 |
NCT04547777 | Phase I | 2141 V-11 + D2C7-IT | Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma | Recruiting | USA | 0 |